Oncostellae is a clinical-stage biopharmaceutical company focused primarily on advancing OST-122, a differentiated, gut-restricted oral small molecule for inflammatory bowel disease (IBD)
Oncostellae is a clinical-stage biopharmaceutical company focused primarily on advancing OST-122, a differentiated, gut-restricted oral small molecule for inflammatory bowel disease (IBD).